查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2092263

肺炎鏈球菌檢測市場－2026-2032年全球市場預測

Pneumococcal Testing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺炎球菌檢測市場將成長至 49.4 億美元，複合年成長率為 8.16%。

主要市場統計數據
基準年 2025 28.5億美元
預計年份：2026年 30.5億美元
預測年份 2032 49.4億美元
複合年成長率 (%) 8.16%

肺炎球菌檢測概述

隨著醫療衛生系統不斷加強對肺炎鏈球菌感染疾病（包括肺炎、腦膜炎、菌血症、中耳炎和敗血症）的檢測、監測和管理，肺炎球菌檢測的重要性日益凸顯。世界衛生組織（WHO）已將肺炎列為兒童感染疾病死亡的主要原因之一，而老年人、免疫力缺乏者和慢性心肺疾病患者患嚴重肺炎鏈球菌感染的風險仍然很高，這進一步凸顯了臨床上對肺炎球菌檢測的需求。診斷方法包括血液培養、腦脊髓液分析、痰液培養、尿液抗原檢測、血清分型、抗生素敏感性試驗以及分子檢測（例如基於PCR的平台）。準確肺炎鏈球菌診斷的需求取決於合理使用抗生素、評估疫苗效力、進行集體爆發調查、監測抗生素抗藥性。隨著結合疫苗計劃改變流行血清型並降低疫苗目標疾病的發生率，實驗室和公共衛生組織越來越需要高度敏感、特異和快速的診斷工具，以區分肺炎鏈球菌感染與其他呼吸道病原體，並確定適當的治療策略。

肺炎球菌診斷的變革性變化

肺炎球菌檢測的格局正從傳統的依賴培養的工作流程轉向整合快速抗原檢測、分子診斷、血清型監測和抗生素抗藥性監測的綜合診斷路徑。雖然培養對於分離株的回收和藥敏試驗仍然至關重要，但其性能會受到既往抗生素暴露和檢體品質的影響。分子診斷的重要性日益凸顯，因為它可以直接從臨床檢體中檢測肺炎球菌DNA，從而支持在侵襲性疾病環境中快速鑑定病原體。同時，呼吸道多重檢測的擴展正在改變臨床醫生評估肺炎和急性呼吸道感染疾病的方式，因為它可以在單一工作流程中識別細菌和病毒共感染病原體。公共衛生優先事項也不斷變化。疫苗的引入和接種計劃的更新需要持續監測血清型分佈，而抗生素抗藥性檢查室。這些變更要求檢查室規範分析前流程，加強品質保證，並將診斷結果與臨床決策支援系統和流行病學報告系統整合。

人工智慧（AI）的累積影響

人工智慧正開始影響肺炎球菌檢測，其角色並非取代核心檢查室的最終診斷，而是影響數據解讀、工作流程最佳化、基於症候群的分診以及監測分析。在臨床環境中，人工智慧驅動的決策支援系統可以整合症狀、影像學觀察、發炎標記、微生物學檢測結果、疫苗接種情況和風險因素，從而幫助確定檢測優先順序並指導經驗性治療。在檢查室中，機器學習可用於最佳化指南利用率，例如支持基於影像的菌落識別、識別異常的藥敏模式以及識別分子或抗原檢測可能具有臨床價值的病例。在公共衛生機構中，人工智慧可以透過分析實驗室報告、抗生素抗藥性趨勢、住院模式和基因組監測結果來增強早期預警系統。然而，有效利用人工智慧需要檢驗的資料集、透明的性能指標、偏差評估、網路安全措施以及臨床醫生的監督。因此，人工智慧的累積影響預計將在以下領域最為顯著：診斷數據的互通性得到保證，實驗室資訊系統得到現代化改造，以及透過管治框架保證自動化洞察具有臨床課責和循證性。

按地區分類的主要發現

在北美，肺炎球菌檢測依賴於成熟的檢查室網路、呼吸道診斷檢測的廣泛應用、對侵襲性肺炎鏈球菌感染的有力監測以及完善的成人和兒童免疫接種計劃。美國和加拿大尤其重視抗菌素抗藥性監測和血清型追蹤。在歐洲，協調的公共衛生監測、國家標準檢查室以及臨床環境中微生物品質標準的廣泛應用均取得了成功，肺炎鏈球菌感染監測與不同醫療保健系統中疫苗政策的評估密切相關。亞太地區的情況瞬息萬變，各有不同。儘管日本、澳洲、韓國、中國、印度和東南亞國協已加強了呼吸道感染疾病診斷系統，但在三級醫療機構和基層醫療機構之間，尤其是在農村和資源匱乏地區，檢測機會仍有差異。在拉丁美洲，實驗室能力正透過免疫接種計畫、哨點監測和區域間合作而得到提升，其中巴西和墨西哥在肺炎鏈球菌感染監測方面發揮主導作用。在中東，尤其是在海灣合作理事會（GCC）國家，醫療衛生系統正增加對醫院診斷能力和數位醫療基礎設施的投資。然而，在非洲，肺炎負擔沉重，部分國家愛滋病毒感染率居高不下，加上檢測能力有限，使得獲得肺炎球菌檢測成為最迫切的需求。持續改善疫苗接種率、檢體運輸系統和即時檢測（POC​​）方法對於擴大診斷覆蓋至關重要。

關鍵區域洞察

在東協，肺炎球菌檢測的優先事項受到高都市區密度、疫苗接種計劃成熟度差異以及在大型醫院以外地區提高快速呼吸道診斷可及性的需求等因素的影響。海灣合作理事會（GCC）國家則專注於先進的醫院診斷、合理使用抗生素以及建立監測系統，以適應其不斷擴大的醫療基礎設施和高水準的跨境流動。歐盟強調統一的疾病監測、檢查室品質標準、疫苗政策評估和抗生素抗藥性報告，並將肺炎球菌診斷作為更廣泛的感染疾病控制的核心要素。金磚國家（BRICS）的檢測情況各不相同。中國和印度正在擴大分子診斷和醫院檢查室能力，巴西和南非在區域感染疾病監測中發揮核心作用，俄羅斯則擁有健全的公共衛生檢測系統。七國集團（G7）國家普遍具備較高的診斷能力、廣泛的參考檢查室能力和完善的疫苗效力監測體系，從而支持肺炎球菌檢測演算法的持續創新。北約成員國的醫療保健系統與北美和歐洲高所得國家的醫療保健系統有很大的重疊，在這些地區，最近的全球衛生危機使得緊急準備、呼吸道病原體監測和檢查室間互通性具有戰略意義。

主要國家的概況

在美國，各國高度重視對侵襲性肺炎鏈球菌感染的廣泛監測、呼吸道病原體檢測的廣泛臨床應用以及合理使用抗生素。同時，在加拿大，省級檢測系統與國家層級的血清型和疫苗有效性監測相結合。墨西哥和巴西正透過公共免疫規劃、兒童疾病監測和擴大檢查室網路來加強其肺炎球菌檢測能力。在歐洲，英國、德國、法國、義大利和西班牙擁有先進的微生物基礎設施、完善的免疫政策和積極的抗菌素抗藥性防治項目，而俄羅斯則繼續依賴公共衛生檢查室和社區層面的感染疾病監測。在中國，隨著人們對肺炎管理和抗菌素抗藥性問題的日益關注，醫院的分子診斷和呼吸道病原體檢測能力正在不斷提升。印度面臨沉重的肺炎負擔，正透過公共衛生舉措、三級醫療檢查室和擴大免疫規劃來改善診斷服務的可近性，但區域間在可近性方面仍存在差異。日本、澳洲和韓國擁有完善的檢查室品管體系，隨著人口老化，成人肺炎鏈球菌感染的重要性日益凸顯，這些國家也建立了完善的監測系統。這些國家表明，肺炎球菌檢測的普及取決於疫苗接種政策、檢查室基礎設施、保險報銷機制、臨床醫生的認知水平，以及將診斷結果與治療和公共衛生措施相結合的能力。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠提高診斷準確性、臨床效用和公共衛生價值，同時避免不必要地增加工作流程複雜性的肺炎球菌檢測策略。關鍵措施包括加強培養和分子檢測的整合，擴大血清型和抗生素抗藥性監測範圍，檢驗相關檢體的檢測方法，以及縮短重症肺炎、腦膜炎和菌血症病例的通報時間。檢查室應投資於員工培訓、外部品質評估、檢體處理標準化以及診斷設備、實驗室資訊系統和公共衛生報告平台之間的互通性。醫療服務提供者應根據免疫接種史、疾病嚴重程度、區域抗藥性模式和抗生素合理使用目標來制定檢測方案。政策制定者和採購團隊應支持在基層醫療、急診、兒童和高感染負擔地區公平地獲得可靠的肺炎球菌診斷。新診斷測試的開發者應優先考慮臨床檢驗、經濟性、易用性、與多參數測試的兼容性以及區分攜帶狀態和侵襲性疾病的能力。臨床醫生、檢查室、疫苗接種計劃和監測機構之間的策略合作對於將檢測結果轉化為快速治療決策和更有效的疾病預防至關重要。

調查方法

本執行摘要是基於對檢驗的肺炎鏈球菌感染和診斷檢測相關的公共衛生、臨床和檢查室證據的系統性審查。資訊來源包括國際和國家公共衛生機構的指南和監測材料、關於肺炎鏈球菌診斷的同行評審文獻、疫苗效力研究、抗菌素抗藥性監測出版物以及經認可的臨床微生物學標準。分析重點在於診斷方法、臨床應用案例、區域實驗室能力、公共衛生監測需求、疫苗誘導的血清型動態變化以及數位化和人工智慧工具在檢查室和流行病學工作流程中的作用。調查方法有意排除市場規模和估算、收入預測、市場佔有率分析和未來展望，而是專注於實證趨勢、營運影響以及醫療保健相關人員的策略考慮。

結論

隨著醫療衛生系統不斷調整以應對肺炎、侵襲性肺炎鏈球菌感染、疫苗相關血清分型和抗生素抗藥性等問題，肺炎球菌檢測正朝著更全面、以監測主導且更具臨床指導意義的方向發展。儘管培養、抗原檢測、分子檢測、血清分型和藥敏試驗各自仍然重要，但只有透過精心設計的診斷演算法，並將其與治療決策和公共衛生報告相結合，才能最大程度地發揮其價值。區域間檢測能力和醫療服務可近性的差異仍然影響著檢測方法的推廣應用，但全球發展方向是明確的：更快、更可靠、更具互通性的肺炎球菌診斷正成為呼吸道感染疾病管理的核心。人工智慧、數位化檢驗和基因組監測若能透過驗證和管治進一步加強，其角色將更加顯著。投資於品管系統、公平取得醫療服務、合理使用抗生素以及疫苗效力監測的相關人員，將更有能力改善肺炎鏈球菌感染高風險病患的治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：肺炎鏈球菌檢測市場：依檢測類型分類

  • 基於培養方法
    • 自動培養方法
    • 傳統培養方法
  • 分子
    • 數位PCR
    • 多重PCR
    • 即時PCR
  • 血清學
  • 肺炎鏈球菌尿抗原檢測（UAT）

第8章：肺炎鏈球菌檢測市場：依樣本類型分類

  • 血
  • 尿
  • 痰
  • 腦脊髓液（CSF）
  • 胸腔積水

第9章：肺炎鏈球菌檢測市場：依應用領域分類

  • 職業篩檢
    • 鼻咽篩檢
    • 口腔和咽部篩檢
  • 診斷
    • 社區型肺炎
    • 腦膜炎
  • 監視
    • 抗菌素抗藥性監測
    • 血清型分佈
  • 疫苗評估

第10章 肺炎鏈球菌檢測市場：依最終用戶分類

  • 診所
  • 醫院
  • 公共衛生檢測實驗室
  • 測試機構

第11章：肺炎鏈球菌檢測市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：肺炎鏈球菌檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 肺炎鏈球菌檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Hain Lifescience GmbH by Bruker Corporation
  • Hologic, Inc.
  • Intec Products, Inc.
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • OpGen Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • Sekisui Diagnostics, LLC
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
Product Code: MRR-4103B31E098A

The Pneumococcal Testing Market is projected to grow by USD 4.94 billion at a CAGR of 8.16% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.85 billion
Estimated Year [2026] USD 3.05 billion
Forecast Year [2032] USD 4.94 billion
CAGR (%) 8.16%

Pneumococcal Testing Overview

Pneumococcal testing is becoming increasingly important as healthcare systems intensify efforts to detect, monitor, and manage infections caused by Streptococcus pneumoniae, including pneumonia, meningitis, bacteremia, otitis media, and sepsis. The clinical need is reinforced by the World Health Organization's recognition of pneumonia as a major infectious cause of death among children, while older adults, immunocompromised individuals, and people with chronic cardiopulmonary conditions remain at elevated risk for severe pneumococcal disease. Diagnostic approaches span blood culture, cerebrospinal fluid testing, sputum culture, urinary antigen testing, serotyping, antimicrobial susceptibility testing, and molecular assays such as PCR-based platforms. Demand for accurate pneumococcal diagnostics is shaped by antibiotic stewardship, vaccine impact assessment, outbreak investigation, and surveillance of antimicrobial resistance. As conjugate vaccine programs alter circulating serotypes and reduce vaccine-type disease, laboratories and public health agencies increasingly require sensitive, specific, and timely testing tools to differentiate pneumococcal infection from other respiratory pathogens and guide appropriate treatment decisions.

Transformative Shifts in Pneumococcal Diagnostics

The pneumococcal testing landscape is shifting from conventional culture-dependent workflows toward integrated diagnostic pathways that combine rapid antigen detection, molecular diagnostics, serotype surveillance, and antimicrobial resistance monitoring. Culture remains essential for isolate recovery and susceptibility testing, but its performance can be affected by prior antibiotic exposure and specimen quality. Molecular methods are gaining relevance because they can detect pneumococcal DNA directly from clinical specimens and support faster identification in invasive disease settings. At the same time, expanded respiratory multiplex testing is changing how clinicians evaluate pneumonia and acute respiratory infections by identifying bacterial and viral co-pathogens within a single workflow. Public health priorities are also transforming demand: vaccine introduction and schedule updates require ongoing serotype distribution monitoring, while antimicrobial resistance surveillance depends on reliable laboratory confirmation. These shifts are encouraging laboratories to standardize pre-analytical processes, strengthen quality assurance, and connect diagnostic outputs with clinical decision support and epidemiological reporting systems.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence pneumococcal testing through data interpretation, workflow optimization, syndromic triage, and surveillance analytics rather than replacing core laboratory confirmation. In clinical settings, AI-enabled decision support can help integrate symptoms, radiology findings, inflammatory markers, microbiology results, vaccination status, and risk factors to prioritize testing and guide empiric therapy. In laboratories, machine learning can support image-based colony recognition, flag unusual susceptibility patterns, and optimize test utilization by identifying cases where molecular or antigen testing may add clinical value. For public health agencies, AI can strengthen early warning systems by analyzing laboratory notifications, antimicrobial resistance trends, hospitalization patterns, and genomic surveillance outputs. However, effective use requires validated datasets, transparent performance metrics, bias assessment, cybersecurity safeguards, and clinician oversight. The cumulative impact of artificial intelligence is therefore expected to be strongest where diagnostic data are interoperable, laboratory information systems are modernized, and governance frameworks ensure that automated insights remain clinically accountable and evidence-based.

Key Regional Insights

In North America, pneumococcal testing is supported by mature laboratory networks, high use of respiratory diagnostics, strong invasive pneumococcal disease surveillance, and established adult and pediatric vaccination programs, with the United States and Canada emphasizing antimicrobial resistance monitoring and serotype tracking. Europe benefits from coordinated public health surveillance, national reference laboratories, and broad clinical adoption of microbiology quality standards, while pneumococcal disease monitoring is closely linked with vaccine policy evaluation across diverse healthcare systems. Asia-Pacific presents a mixed but rapidly evolving environment: Japan, Australia, South Korea, China, India, and ASEAN countries are strengthening respiratory infection diagnostics, yet access varies between tertiary centers and primary care settings, particularly in rural and resource-constrained areas. Latin America is advancing laboratory capacity through immunization programs, sentinel surveillance, and regional collaboration, with Brazil and Mexico playing prominent roles in pneumococcal disease monitoring. The Middle East, particularly GCC health systems, shows increasing investment in hospital diagnostics and digital health infrastructure, while Africa faces the highest need for accessible pneumococcal testing due to pneumonia burden, HIV prevalence in some countries, and constraints in laboratory capacity; ongoing improvements in vaccination coverage, specimen referral systems, and point-of-care approaches are central to expanding diagnostic reach.

Key Group Insights

Across ASEAN, pneumococcal testing priorities are shaped by dense urban populations, variable vaccine program maturity, and the need to improve access to rapid respiratory diagnostics beyond major hospitals. GCC countries are focusing on advanced hospital-based diagnostics, antimicrobial stewardship, and surveillance systems aligned with expanding healthcare infrastructure and high levels of cross-border travel. The European Union emphasizes harmonized disease surveillance, laboratory quality standards, vaccine policy assessment, and antimicrobial resistance reporting, making pneumococcal diagnostics a core component of broader infectious disease control. BRICS countries reflect diverse testing realities: China and India are expanding molecular and hospital laboratory capacity, Brazil and South Africa are central to regional infectious disease surveillance, and Russia maintains a strong public health laboratory structure. G7 countries generally demonstrate high diagnostic readiness, extensive reference laboratory capabilities, and robust vaccine impact monitoring, supporting continued innovation in pneumococcal testing algorithms. NATO member states overlap substantially with high-income health systems in North America and Europe, where preparedness planning, respiratory pathogen surveillance, and laboratory interoperability have gained strategic importance following recent global health emergencies.

Key Country Insights

The United States has extensive invasive pneumococcal disease surveillance, broad clinical use of respiratory panels, and strong emphasis on antibiotic stewardship, while Canada combines provincial laboratory systems with national monitoring of serotypes and vaccine impact. Mexico and Brazil are strengthening pneumococcal testing through public immunization programs, pediatric disease surveillance, and expanding laboratory networks. In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain advanced microbiology infrastructure, established vaccination policies, and active antimicrobial resistance programs, while Russia continues to rely on public health laboratories and regional infectious disease surveillance. China is expanding hospital-based molecular diagnostics and respiratory pathogen testing capacity, supported by growing attention to pneumonia management and antimicrobial resistance. India faces a high pneumonia burden and is increasing access to diagnostics through public health initiatives, tertiary care laboratories, and vaccination expansion, though access gaps remain across geographies. Japan, Australia, and South Korea have strong laboratory quality systems, aging populations that increase adult pneumococcal disease relevance, and established surveillance frameworks. Together, these countries illustrate how pneumococcal testing adoption depends on vaccine policy, laboratory infrastructure, reimbursement pathways, clinician awareness, and the ability to connect diagnostic results with treatment and public health action.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize pneumococcal testing strategies that improve diagnostic accuracy, clinical utility, and public health value without adding unnecessary workflow complexity. Key actions include strengthening culture and molecular testing integration, expanding serotype and antimicrobial resistance surveillance, validating assays across relevant specimen types, and improving turnaround time for severe pneumonia, meningitis, and bacteremia cases. Laboratories should invest in staff training, external quality assessment, standardized specimen handling, and interoperability between diagnostic instruments, laboratory information systems, and public health reporting platforms. Healthcare providers should align testing algorithms with vaccination history, disease severity, local resistance patterns, and antibiotic stewardship goals. Policymakers and procurement teams should support equitable access to reliable pneumococcal diagnostics in primary care, emergency departments, pediatric settings, and high-burden regions. Developers of new assays should focus on clinical validation, affordability, ease of use, multiplex compatibility, and differentiation between colonization and invasive disease. Strategic collaboration among clinicians, laboratories, immunization programs, and surveillance authorities will be essential to translate test results into faster care decisions and stronger disease prevention.

Research Methodology

This executive summary is based on a structured review of verified public health, clinical, and laboratory evidence related to pneumococcal disease and diagnostic testing. Sources considered include guidance and surveillance materials from global and national public health agencies, peer-reviewed literature on Streptococcus pneumoniae diagnostics, vaccine impact studies, antimicrobial resistance monitoring publications, and recognized clinical microbiology standards. The analysis focused on diagnostic modalities, clinical use cases, regional testing capacity, public health surveillance needs, vaccine-driven serotype dynamics, and the role of digital and AI-enabled tools in laboratory and epidemiological workflows. Information was evaluated for relevance, recency, consistency across credible sources, and applicability to pneumococcal testing in both high-resource and resource-limited settings. The methodology intentionally excludes market sizing, revenue estimation, market share analysis, and forecasting, concentrating instead on evidence-backed trends, operational implications, and strategic considerations for healthcare stakeholders.

Conclusion

Pneumococcal testing is evolving into a more integrated, surveillance-driven, and clinically actionable field as healthcare systems respond to pneumonia burden, invasive pneumococcal disease, vaccine-related serotype shifts, and antimicrobial resistance. Culture, antigen testing, molecular assays, serotyping, and susceptibility testing each remain important, but their greatest value emerges when they are deployed through well-designed diagnostic algorithms and connected to treatment decisions and public health reporting. Regional differences in laboratory capacity and healthcare access continue to shape adoption, yet the global direction is clear: faster, more reliable, and more interoperable pneumococcal diagnostics are becoming central to respiratory infection management. Artificial intelligence, digital reporting, and genomic surveillance can further enhance impact when implemented with validation and governance. Stakeholders that invest in quality systems, equitable access, antimicrobial stewardship alignment, and vaccine impact monitoring will be better positioned to improve outcomes for patients at risk of pneumococcal disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pneumococcal Testing Market, by Type Of Test

  • 7.1. Introduction
  • 7.2. Culture Based
    • 7.2.1. Automated Culture
    • 7.2.2. Conventional Culture
  • 7.3. Molecular
    • 7.3.1. Digital PCR
    • 7.3.2. Multiplex PCR
    • 7.3.3. Real Time PCR
  • 7.4. Serological
  • 7.5. Pneumococcal Urinary Antigen Test (UAT)

8. Pneumococcal Testing Market, by Sample Type

  • 8.1. Introduction
  • 8.2. Blood
  • 8.3. Urine
  • 8.4. Sputum
  • 8.5. Cerebrospinal Fluid (CSF)
  • 8.6. Pleural Fluid

9. Pneumococcal Testing Market, by Application

  • 9.1. Introduction
  • 9.2. Carrier Screening
    • 9.2.1. Nasopharyngeal Screening
    • 9.2.2. Oropharyngeal Screening
  • 9.3. Diagnosis
    • 9.3.1. Community Acquired Pneumonia
    • 9.3.2. Meningitis
  • 9.4. Surveillance
    • 9.4.1. Antibiotic Resistance Monitoring
    • 9.4.2. Serotype Distribution
  • 9.5. Vaccine Evaluation

10. Pneumococcal Testing Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Hospitals
  • 10.4. Public Health Labs
  • 10.5. Reference Labs

11. Pneumococcal Testing Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Pneumococcal Testing Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Pneumococcal Testing Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. Becton, Dickinson and Company
  • 15.3. Bio-Rad Laboratories, Inc.
  • 15.4. bioMerieux SA
  • 15.5. Danaher Corporation
  • 15.6. DiaSorin S.p.A.
  • 15.7. Eurofins Scientific SE
  • 15.8. F. Hoffmann-La Roche Ltd
  • 15.9. Hain Lifescience GmbH by Bruker Corporation
  • 15.10. Hologic, Inc.
  • 15.11. Intec Products, Inc.
  • 15.12. Luminex Corporation
  • 15.13. Meridian Bioscience, Inc.
  • 15.14. OpGen Inc.
  • 15.15. QIAGEN N.V.
  • 15.16. Quest Diagnostics Incorporated
  • 15.17. Quidel Corporation
  • 15.18. Sekisui Diagnostics, LLC
  • 15.19. Siemens Healthineers AG
  • 15.20. Thermo Fisher Scientific Inc.
  • 15.21. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMOCOCCAL TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PNEUMOCOCCAL TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PNEUMOCOCCAL TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PNEUMOCOCCAL TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PNEUMOCOCCAL TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL PNEUMOCOCCAL TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMOCOCCAL TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CULTURE BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CULTURE BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CULTURE BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATED CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATED CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATED CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONVENTIONAL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONVENTIONAL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONVENTIONAL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MOLECULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MOLECULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLEX PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLEX PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIPLEX PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL REAL TIME PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL REAL TIME PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL REAL TIME PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SEROLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SEROLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEROLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMOCOCCAL URINARY ANTIGEN TEST (UAT) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMOCOCCAL URINARY ANTIGEN TEST (UAT) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMOCOCCAL URINARY ANTIGEN TEST (UAT) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SPUTUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SPUTUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SPUTUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PLEURAL FLUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PLEURAL FLUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PLEURAL FLUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARRIER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARRIER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NASOPHARYNGEAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NASOPHARYNGEAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NASOPHARYNGEAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OROPHARYNGEAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OROPHARYNGEAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OROPHARYNGEAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMMUNITY ACQUIRED PNEUMONIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMMUNITY ACQUIRED PNEUMONIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMMUNITY ACQUIRED PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MENINGITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MENINGITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MENINGITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SURVEILLANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBIOTIC RESISTANCE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBIOTIC RESISTANCE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBIOTIC RESISTANCE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SEROTYPE DISTRIBUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SEROTYPE DISTRIBUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SEROTYPE DISTRIBUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VACCINE EVALUATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VACCINE EVALUATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VACCINE EVALUATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PUBLIC HEALTH LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PUBLIC HEALTH LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PUBLIC HEALTH LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL REFERENCE LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL REFERENCE LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL REFERENCE LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 165. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 166. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 167. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 170. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 171. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 195. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 196. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 197. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 200. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 201. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 205. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 206. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 207. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 210. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 211. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 231. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 253. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 281. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 282. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 283. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 291. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 292. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 293. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 301. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 302. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 303. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 308. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 310. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 311. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 312. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 313. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 326. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 328. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 330. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 331. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 332. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 333. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 336. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 337. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 338. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 340. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 341. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 342. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 343. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 344. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 346. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 347. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 348. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 350. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 351. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 352. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 354. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 355. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 356. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 357. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 358. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 359. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 360. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 361. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 362. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 363. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 364. GLOBAL PNEUMOCOCCAL TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 365. GLOBAL PNEUMOCOCCAL TESTING MARKET, F